{"id":62490,"date":"2026-01-14T07:06:04","date_gmt":"2026-01-14T06:06:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/"},"modified":"2026-01-14T07:06:04","modified_gmt":"2026-01-14T06:06:04","slug":"toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/","title":{"rendered":"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nGalderma will present data on Relfydess<sup>\u00ae<\/sup> (RelabotulinumtoxinA) \u2013 the first and only ready-to-use liquid neuromodulator designed with PEARL\u2122 Technology \u2013 which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow\u2019s feet (lateral canthal lines)<sup>1-3<\/sup><\/li>\n<li>\nDysport<sup>\u00ae<\/sup> (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction after treatment of frown lines will also be presented<sup>4,5<\/sup><\/li>\n<li>\nGalderma will also present a Masterclass on the science behind Relfydess, demonstrating how the company is shaping the future of neuromodulation<\/li>\n<\/ul>\n<p>ZUG, Switzerland&#8211;(BUSINESS WIRE)&#8211;Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The company will share data from five abstracts on two neuromodulators from its portfolio, Relfydess \u2013 the first and only ready-to-use liquid neuromodulator designed with PEARL Technology \u2013 and Dysport. Additionally, Galderma will be hosting a Relfydess Masterclass in which expert speakers will delve into the science and clinical data behind Relfydess.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/5\/GALDERMA_LOGO_BLACK_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/22\/GALDERMA_LOGO_BLACK_RGB.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/5\/GALDERMA_LOGO_BLACK_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/21\/GALDERMA_LOGO_BLACK_RGB.jpg\"><\/a><\/p>\n<table cellspacing=\"0\" class=\"bwblockalignl bwwidth100 bwtablemarginb\">\n<tr>\n<td class=\"bwwidth99 bwvertalignt bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u201cAt TOXINS 2026, we will demonstrate our continued leadership in neuromodulation through updates on our leading portfolio, and an educational session on Relfydess, an innovative, science-backed neuromodulator that delivers advanced performance. As the only company with a portfolio of neuromodulators, we\u2019re building on our heritage in the space by developing next-generation solutions that address the evolving expectations of both patients and practitioners.\u201d<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>GLOBAL HEAD OF R&amp;D<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>GALDERMA<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nRelfydess presentations include two encore post-hoc subgroup analyses of pooled phase III READY program data in moderate-to-severe frown lines and crow\u2019s feet. These data showed:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n&gt;98% and &gt;88% investigator-assessed responder rates after one month of treatment in patients with frown lines and crow\u2019s feet, respectively<sup>3<\/sup><\/li>\n<li>\n&gt;24 weeks median time to return to baseline severity for both frown lines and crow\u2019s feet, as assessed by both patients and investigators<sup>2<\/sup><\/li>\n<\/ul>\n<p>\nAdditionally, new Relfydess data includes results from an in vivo head-to-head study of Relfydess and OnabotulinumtoxinA showing similar and limited levels of diffusion in a rat model.<sup>6<\/sup><\/p>\n<p>\nTogether, these analyses provided further evidence to support Relfydess\u2019 rapid onset and efficacy through six months regardless of previous neuromodulator treatment, robust safety profile, high patient satisfaction, and improved well-being.<sup>2,3,6<\/sup><\/p>\n<p>\nGalderma will also be hosting a Relfydess Masterclass at TOXINS 2026 in which expert speakers, Dr. Joanna Czuwara and Dr. Birgit Blessman-Gurk, will discuss clinical data, real-world treatment experience, and the science behind Relfydess\u2019 PEARL Technology. The session will feature insights into its rapid onset, long duration, and scientific differentiation principles and will take place from <b>15:50 \u2013 16:20 CET<\/b> on <b>Thursday, January 15<\/b> in the <b>Educational Theatre<\/b>.<\/p>\n<p>\nFurthermore, abstracts investigating patient and practitioner satisfaction when using Dysport to treat frown lines will also be presented at the conference, including results from a real-world study of repeated Dysport treatment in China showing up to 100% patient satisfaction three weeks after three treatment cycles.<sup>4,5<\/sup><\/p>\n<p>\n<b>Establishing clear leadership in neuromodulation<\/b><\/p>\n<p>\nGalderma\u2019s data and activities at TOXINS 2026 demonstrate how its innovative and unique neuromodulator portfolio consistently meets the needs of patients and practitioners, setting the company apart as a leader in this field.<\/p>\n<p>\nToday, Galderma is well positioned to be the leader in all aspects of Injectable Aesthetics, having the in-house capabilities to discover, research, develop, manufacture, and market best-in-class products.<\/p>\n<p>\nMore details on Galderma\u2019s scientific presentations at TOXINS 2026 can be found <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.galderma.com%2Fnews%2Ftoxins-2026-galdermas-scientific-presentations&amp;esheet=54395830&amp;newsitemid=20260113854672&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=2bda5c0ce43b4697261f3f45c28ddab7\" rel=\"nofollow\" shape=\"rect\">here<\/a>.<\/p>\n<p>\n<b>About Relfydess (RelabotulinumtoxinA)<br \/>\n<br \/><\/b>Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator designed with PEARL Technology that is designed to preserve molecule integrity.<sup>1<\/sup> PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.<sup>1,7,8<\/sup> Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose\/volume every time.<sup>9,10<\/sup> It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. Relfydess received a marketing authorization in several markets. RelabotulinumtoxinA is an investigational drug product in the U.S. Authorization conditions may vary internationally.<\/p>\n<p>\n<b>About Galderma<br \/>\n<br \/><\/b>Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body\u2019s largest organ \u2013 the skin \u2013 meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.galderma.com&amp;esheet=54395830&amp;newsitemid=20260113854672&amp;lan=en-US&amp;anchor=www.galderma.com&amp;index=2&amp;md5=40f334309d34cc7dde8a5d76a66ef365\" rel=\"nofollow\" shape=\"rect\">www.galderma.com<\/a>.\u00a0<\/p>\n<p>\n<b>References<\/b><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nShridharani SM, et al. Efficacy and safety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: Results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines. <i>Aesthet Surg J<\/i>. 2024; 44(12):1330-1340. doi: 10.1093\/asj\/sjae131.<\/li>\n<li>\nAblon G, et al. RelaBoNT-A Treatment of Glabellar Lines and Lateral Canthal Lines of Different Baseline Severity: Subgroup Analyses of Pooled Phase III Study Data. Abstract #0080 presented at TOXINS; January 14-17, 2026; Madrid, Spain.<\/li>\n<li>\nCox SE, et al. RelabotulinumtoxinA Treatment Improved Moderate to Severe Glabellar Lines and Lateral Canthal Lines Regardless of Baseline Toxin Naivety: Subgroup Analyses of Pooled Phase 3 Study Data. Abstract #0079 presented at TOXINS; January 14-17, 2026; Madrid, Spain.<\/li>\n<li>\nSchlessinger J, et al. High Subject Satisfaction With AbobotulinumtoxinA Treatment of Glabellar Lines Post-Marketing Across the Globe. Abstract #0070 presented at TOXINS; January 14-17, 2026; Madrid, Spain.<\/li>\n<li>\nHuang J, et al. Subject and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatments of Glabellar Lines in Chinese Subjects: Results From a Real-World Study. Abstract #0075 presented at TOXINS; January 14-17, 2026; Madrid, Spain.<\/li>\n<li>\nNicod\u00e8m E, et al. Similar and Limited In Vivo Diffusion for relaBoNT-A and onaBoNT-A. Abstract #0103 presented at TOXINS; January 14-17, 2026; Madrid, Spain.<\/li>\n<li>\nAblon G, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, an investigational liquid botulinum toxin: clinical efficacy and safety results from the READY-2 phase 3 trial. <i>Toxicon<\/i>. 2024; 237(1): 107353. doi: 10.1026\/j.toxicon.2024.107353.<\/li>\n<li>\nRelfydess<sup>\u00ae<\/sup>. EU Summary of Product Characteristics.<\/li>\n<li>\nSundberg AL and Stahl U. Relabotulinum toxin &#8211; a novel, high purity BoNT-A1 in liquid formulation. Presented at TOXINS; January 16-17, 2021; virtual meeting.<\/li>\n<li>\nDo M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) &#8211; relabotulinumtoxinA. Presented at TOXINS; July 27-30, 2022; Louisiana, United States.<\/li>\n<\/ol>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nChristian Marcoux, M.Sc.<br \/>\n<br \/>Chief Communications Officer<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:c&#104;&#114;&#105;&#115;&#116;&#105;&#97;&#110;&#46;&#109;&#x61;&#x72;&#x63;&#x6f;&#x75;&#x78;&#x40;&#x67;&#x61;&#x6c;&#x64;&#x65;&#x72;&#x6d;&#x61;&#46;com\" rel=\"nofollow\" shape=\"rect\">&#x63;&#104;r&#x69;&#115;t&#x69;&#97;n&#x2e;&#109;a&#x72;&#99;o&#x75;&#120;&#64;&#x67;&#97;l&#x64;&#101;r&#x6d;&#97;&#46;&#x63;&#111;m<\/a><br \/>+41 76 315 26 50<\/p>\n<p>Richard Harbinson<br \/>\n<br \/>Corporate Communications Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x72;&#105;&#99;&#104;&#97;&#114;&#100;&#46;harb&#x69;&#x6e;&#x73;&#x6f;&#x6e;&#x40;&#x67;&#x61;&#x6c;&#100;&#101;&#114;&#109;&#97;&#46;&#99;om\" rel=\"nofollow\" shape=\"rect\">r&#105;&#99;&#x68;&#x61;r&#100;&#46;&#x68;&#x61;&#x72;b&#105;&#110;&#x73;&#x6f;n&#64;&#103;&#x61;&#x6c;&#x64;e&#114;&#109;&#x61;&#x2e;co&#109;<\/a><br \/>+41 76 210 60 62<\/p>\n<p>C\u00e9line Buguet<br \/>\n<br \/>Franchises and R&amp;D Communications Director<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o&#58;&#99;&#x65;&#x6c;&#x69;n&#101;&#46;&#x62;&#x75;gu&#101;&#x74;&#x40;&#x67;a&#108;&#100;&#x65;&#x72;ma&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x63;&#101;l&#x69;&#110;e&#x2e;&#98;u&#x67;&#117;e&#x74;&#64;g&#x61;&#108;d&#x65;&#114;m&#x61;&#46;c&#x6f;&#109;<\/a><br \/>+41 76 249 90 87<\/p>\n<p>Emil Ivanov<br \/>\n<br \/>Head of Strategy, Investor Relations, and ESG<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;&#111;&#x3a;&#x65;&#109;i&#x6c;&#46;i&#x76;&#x61;&#110;o&#x76;&#64;g&#x61;&#x6c;&#100;e&#x72;&#109;a&#x2e;&#x63;&#111;m\" rel=\"nofollow\" shape=\"rect\">&#101;&#x6d;&#105;&#x6c;&#46;&#x69;v&#97;&#x6e;&#111;&#x76;&#64;&#x67;a&#x6c;d&#101;&#x72;&#109;&#x61;&#46;&#x63;o&#x6d;<\/a><br \/>+41 21 642 78 12<\/p>\n<p>Jessica Cohen<br \/>\n<br \/>Investor Relations and Strategy Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x6a;&#x65;&#115;s&#x69;&#x63;&#97;&#46;&#x63;&#x6f;&#104;e&#x6e;&#64;&#103;a&#x6c;&#100;e&#x72;&#x6d;&#97;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">&#x6a;&#101;&#x73;&#x73;&#105;&#x63;&#x61;&#46;&#x63;&#x6f;&#104;&#x65;&#x6e;&#64;&#x67;&#x61;l&#x64;&#101;r&#x6d;&#97;&#46;&#x63;&#111;m<\/a><br \/>+41 21 642 76 43<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Galderma will present data on Relfydess\u00ae (RelabotulinumtoxinA) \u2013 the first and only ready-to-use liquid neuromodulator designed with PEARL\u2122 Technology \u2013 which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow\u2019s feet (lateral canthal lines)1-3 Dysport\u00ae (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62490","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Galderma will present data on Relfydess\u00ae (RelabotulinumtoxinA) \u2013 the first and only ready-to-use liquid neuromodulator designed with PEARL\u2122 Technology \u2013 which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow\u2019s feet (lateral canthal lines)1-3 Dysport\u00ae (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-14T06:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/22\/GALDERMA_LOGO_BLACK_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics\",\"datePublished\":\"2026-01-14T06:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/\"},\"wordCount\":1126,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260113854672\\\/en\\\/2690950\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/\",\"name\":\"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260113854672\\\/en\\\/2690950\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"datePublished\":\"2026-01-14T06:06:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260113854672\\\/en\\\/2690950\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260113854672\\\/en\\\/2690950\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/","og_locale":"en_US","og_type":"article","og_title":"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics - Pharma Trend","og_description":"Galderma will present data on Relfydess\u00ae (RelabotulinumtoxinA) \u2013 the first and only ready-to-use liquid neuromodulator designed with PEARL\u2122 Technology \u2013 which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow\u2019s feet (lateral canthal lines)1-3 Dysport\u00ae (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-14T06:06:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics","datePublished":"2026-01-14T06:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/"},"wordCount":1126,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/","url":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/","name":"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","datePublished":"2026-01-14T06:06:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260113854672\/en\/2690950\/22\/GALDERMA_LOGO_BLACK_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/toxins-2026-clinical-updates-on-galdermas-leading-neuromodulator-portfolio-further-reinforce-its-leadership-in-injectable-aesthetics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TOXINS 2026: Clinical Updates on Galderma\u2019s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62490"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62490\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}